Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Stephanie Carr

Neurology Albany, GA Nurse Practitioner

NPI 1225801244 CMS profile 11525760

2709 Meredyth Drive, Suite 340, Albany, GA 31707

Open in the dashboard

General payments

$3,593

176 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Carr of Albany, GA is reported in the CMS Open Payments database as having received $3,593 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,440 69
2024 General $2,096 104
2023 General $57 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Carr
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Stephanie Carr were reported at $1,440. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Stephanie Carr Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $57 $464 $119–$2,312 $160
2024 $2,096 $468 $119–$2,323 $164
2025 $1,440 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Neurelis, Inc. $377 18 payments
  2. AbbVie, Inc. $321 20 payments
  3. Eisai Inc. $291 14 payments
  4. Biogen, Inc. $284 15 payments
  5. Pfizer Inc. $262 13 payments
  6. UCB, Inc. $247 11 payments
  7. SK Life Science, Inc. $200 9 payments
  8. TG Therapeutics, Inc. $184 8 payments
  9. Neurocrine Biosciences, Inc. $181 8 payments
  10. Lilly USA, LLC $168 9 payments
  11. Other $1,077 51 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,593 176 payments
Products named General payments · program years 2023–2025
  1. VALTOCO $377 18 payments
  2. Leqembi $291 14 payments
  3. VUMERITY $284 15 payments
  4. UBRELVY $270 17 payments
  5. TYSABRI $223 14 payments
  6. NURTEC ODT $202 10 payments
  7. ZAVZPRET $202 10 payments
  8. QULIPTA $191 14 payments
  9. BRIUMVI $184 8 payments
  10. Briviact $183 8 payments
  11. Other $1,691 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,360

Median for Nurse Practitioner: 389

Drug cost

$216,271

Median for Nurse Practitioner: $21,885

Branded share of claims

14.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 59 $70,762
Qulipta Atogepant Brand 53 $57,483
Ubrelvy Ubrogepant Brand 37 $47,361
Aimovig Autoinjector Erenumab-Aooe Brand 15 $10,895
Emgality Pen Galcanezumab-Gnlm Brand 13 $8,492
Lacosamide Generic 29 $3,648
Rivastigmine Generic 30 $3,444
Memantine Hcl Generic 176 $3,266
Levetiracetam Generic 108 $2,490
Donepezil Hcl Generic 358 $2,198

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$15,744

Medicare's payments for the services billed

Medicare patients

196

Average age 73

Services billed

228

118 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Alzheimer's or dementia 41%
Diabetes 38%
Depression 37%
Chronic kidney disease 35%
Ischemic heart disease 19%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $226
$226 — —
Leqembi
  • Eisai Inc. $223
$223 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $181
$181 — —
VUMERITY
  • Biogen, Inc. $139
$139 — —
Briviact
  • UCB, Inc. $138
$138 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record